Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro

被引：8

作者：

Dong, HL ^{[1
]}

Sui, YF ^{[1
]}

Li, ZS ^{[1
]}

Qu, P ^{[1
]}

Wu, W ^{[1
]}

Ye, J ^{[1
]}

Zhang, XM ^{[1
]}

Lu, SY ^{[1
]}

机构：

[1] Fourth Mil Med Univ, Dept Pathol, Xian 710032, Shaanxi, Peoples R China

来源：

CANCER LETTERS | 2004年 / 211卷 / 02期

关键词：

hepatocellular carcinoma; MAGE-n; HLA-A2; cytotoxic T lymphocytes;

D O I：

10.1016/j.canlet.2004.02.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MAGE-n is a new member of MAGE gene family and has been demonstrated closely associated with hepatocellular carcinoma (HCC). In this study, MAGE-n-derived peptide-specific cytotoxic T lymphocytes (CTL) were induced from the peripheral blood mononuclear cells of healthy donors by multiple stimulations with HLA-A2-restricted MAGE-n peptide-pulsed T2 cells. The induced CTLs exhibited specific lysis against T2 cells pulsed with the peptide and HLA-A2(+) HCC cells expressing MAGE-n, while HLA-A2(+) HCC cell lines that did not express MAGE-n could not be recognized by the CTLs. The peptide-specific activity was inhibited by anti-MHC class I monoclonal antibody. These results suggested the MAGE-n peptide could be a potential target of specific immunotherapy for HLA-A2 patients with HCC. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：219 / 225

页数：7

共 19 条

[1] Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination:: Cessation of CTL responses is associated with disease progression [J].

Andersen, MH ;

Keikavoussi, P ;

Bröcker, EB ;

Schuler-Thurner, B ;

Jonassen, M ;

Sondergaard, I ;

Straten, PT ;

Becker, JC ;

Kämpgen, E .

INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) :820-824

[2] BAGE - A NEW GENE ENCODING AN ANTIGEN RECOGNIZED ON HUMAN MELANOMAS BY CYTOLYTIC T-LYMPHOCYTES [J].

BOEL, P ;

WILDMANN, C ;

SENSI, ML ;

BRASSEUR, R ;

RENAULD, JC ;

COULIE, P ;

BOON, T ;

VANDERBRUGGEN, P .

IMMUNITY, 1995, 2 (02) :167-175

[3] Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells [J].

Brossart, P ;

Wirths, S ;

Stuhler, G ;

Reichardt, VL ;

Kanz, L ;

Brugger, W .

BLOOD, 2000, 96 (09) :3102-3108

[4] Immunotherapy of hepatocellular carcinoma [J].

Butterfield, LH ;

Ribas, A .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (02) :123-133

[5] Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes [J].

Eifuku R. ;

Takenoyama M. ;

Yoshino I. ;

Imahayashi S. ;

So T. ;

Yasuda M. ;

Sugaya M. ;

Yasumoto K. .

International Journal of Clinical Oncology, 2001, 6 (1) :34-39

[6] Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1,-A2,-A3,-A4,-A6,-A10, and-A12 tumor antigens: Implication in a broad-spectrum tumor immunotherapy [J].

Graff-Dubois, S ;

Faure, O ;

Gross, DA ;

Alves, P ;

Scardino, A ;

Chouaib, S ;

Lemonnier, FA ;

Kosmatopoulos, K .

JOURNAL OF IMMUNOLOGY, 2002, 169 (01) :575-580

[7] Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24 [J].

Katsura, F ;

Eura, M ;

Chikamatsu, K ;

Oiso, M ;

Yumoto, E ;

Ishikawa, T .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2000, 30 (03) :117-121

[8] Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells [J].

Ladhams, A ;

Schmidt, C ;

Sing, G ;

Butterworth, L ;

Fielding, G ;

Tesar, P ;

Strong, R ;

Leggett, B ;

Powell, L ;

Maddern, G ;

Ellem, K ;

Cooksley, G .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (08) :889-896

[9]

Li J, 1996, CLIN CANCER RES, V2, P1619

[10]

Ming LH, 1999, CHIN J IMMUNOL, V15, P305

← 1 2 →